Ligne de temps

Laleh Majlessi

Directeur(trice) de Recherche

30 août 2025

publication

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses

Lire plus

04 juil. 2025

publication

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.

Lire plus

10 juin 2024

publication

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

Lire plus

02 avr. 2024

publication

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.

Lire plus

07 sept. 2023

publication

Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.

Lire plus

01 janv. 2023

publication

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma.

Lire plus

01 janv. 2023

publication

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

Lire plus

14 sept. 2022

publication

A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity.

Lire plus

26 juil. 2022

publication

A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity.

Lire plus

27 avr. 2022

publication

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

Lire plus

07 déc. 2021

publication

Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Lire plus

29 juil. 2021

team

Laboratoire Commun Pasteur – TheraVectys

Lire plus

09 avr. 2021

event

Seminar DPT Microbiology “Intranasal Vaccination with a Lentiviral Vector Fully Protects Lungs and Brain against SARS-CoV-2”, Laleh Majlessi

Lire plus

06 avr. 2021

project

Modeling SARS-CoV-2 infection and immune responses in humanized mouse models

Lire plus

01 mars 2019

publication

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers Against Tuberculosis

Lire plus

11 juil. 2018

publication

Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity

Lire plus

18 juin 2018

publication

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection

Lire plus

24 avr. 2018

publication

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors

Lire plus

17 janv. 2018

publication

Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus

Lire plus

28 août 2017

publication

Un nouveau concept pour améliorer le vaccin antituberculeux

Lire plus

14 mars 2017

publication

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection

Lire plus

01 févr. 2017

publication

Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis

Lire plus

01 nov. 2016

publication

The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages

Lire plus

26 sept. 2016

publication

ESX secretion systems: mycobacterial evolution to counter host immunity

Lire plus

28 juil. 2016

publication

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection

Lire plus

31 mai 2016

publication

Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access

Lire plus

28 avr. 2016

publication

A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence of Mycobacterium marinum in multiple hosts

Lire plus

27 janv. 2016

publication

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence

Lire plus

02 déc. 2015

event

EMBO Conference Tuberculosis 2016

Lire plus

25 nov. 2015

publication

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis

Lire plus

10 juin 2015

publication

Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity

Lire plus

11 mai 2015

team

Pathogénomique Mycobactérienne Intégrée

Lire plus

01 mars 2015

publication

Release of mycobacterial antigens

Lire plus

13 févr. 2015

publication

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection

Lire plus

06 févr. 2015

publication

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo

Lire plus

06 janv. 2013

publication

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis

Lire plus

19 avr. 2012

publication

Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion: encoded PE-PPE proteins predicts vaccine potential

Lire plus

Un petit guide pour l'utilisation de la recherche avancée :

Lentiviral vector-based T-cell vaccines against Zika and yellow fever viruses

Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity.

T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.

A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.

Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine.

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma.

Preclinical proof of concept of a tetravalent lentiviral T-cell vaccine against dengue viruses.

A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4+ T-cell immunity.

A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4+ T cell immunity.

An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.

Laboratoire Commun Pasteur – TheraVectys

Seminar DPT Microbiology “Intranasal Vaccination with a Lentiviral Vector Fully Protects Lungs and Brain against SARS-CoV-2”, Laleh Majlessi

Modeling SARS-CoV-2 infection and immune responses in humanized mouse models

Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers Against Tuberculosis

Unexpected genomic and phenotypic diversity of Mycobacterium africanum Lineage 5 affects drug resistance, protein secretion and immunogenicity

RD5-mediated lack of PE_PGRS and PPE-MPTR export in BCG vaccine strains results in strong reduction of antigenic repertoire but little impact on protection

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors

Identification of genes required for Mycobacterium abscessus growth in vivo with a prominent role of the ESX-4 locus

Un nouveau concept pour améliorer le vaccin antituberculeux

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection

Colonization with Helicobacter is concomitant with modified gut microbiota and drastic failure of the immune control of Mycobacterium tuberculosis

The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages

ESX secretion systems: mycobacterial evolution to counter host immunity

CD4+ T Cells Recognizing PE/PPE Antigens Directly or via Cross Reactivity Are Protective against Pulmonary Mycobacterium tuberculosis Infection

Perspectives on mycobacterial vacuole-to-cytosol translocation: the importance of cytosolic access

A unique PE_PGRS protein inhibiting host cell cytosolic defenses and sustaining full virulence of Mycobacterium marinum in multiple hosts

pks5-recombination-mediated surface remodelling in Mycobacterium tuberculosis emergence

EMBO Conference Tuberculosis 2016

Revisiting the role of phospholipases C in virulence and the lifecycle of Mycobacterium tuberculosis

Mycobacterium tuberculosis Meets the Cytosol: The Role of cGAS in Anti-mycobacterial Immunity

Pathogénomique Mycobactérienne Intégrée

Release of mycobacterial antigens

ESX/type VII secretion systems of mycobacteria: Insights into evolution, pathogenicity and protection

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo

Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis

Strong immunogenicity and cross-reactivity of Mycobacterium tuberculosis ESX-5 type VII secretion: encoded PE-PPE proteins predicts vaccine potential